HIKMA, A CONVINCINGLY DIFFERENT PHARMA (ADD; 12% UPSIDE)
23/12/20 -"Since our last endorsement in April 2020, it has been a seesaw ride for the generic drugs manufacturer, Hikma (Add, UK). While the reiteration of its FY20 targets (in May), at a time when peers were ..."
Pages
56
Language
English
Published on
23/12/20
You may also be interested by these reports :
25/08/25
Attractive return potential remains – Confidence slightly raised
22/08/25
Though missing expectations, Novonesis demonstrated strong momentum in H1 2025, achieving 9% organic growth and 8% in Q2, resulting in a narrowed ...
21/08/25
Guidance reaffirmed while FX and destocking mask momentum
20/08/25
Following Donald Trump’s tariff threats and given the generic/biosimilar medicine makers’ relatively thin profitability, the markets were quick to ...